Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-01-30
2007-01-30
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S144000, C546S148000, C514S312000, C514S311000
Reexamination Certificate
active
10506748
ABSTRACT:
Heterocyclic amides of formula (1)wherein:is a single or double bond;A is phenylene or heteroarylene;m is 0, 1 or 2;n is 0, 1 or 2;R1is selected from for example halo, nitro, cyano, hydroxy, carboxy;R2is hydrogen, hydroxy or carboxy;R3is selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C1-4alkyl(optionally substituted by 1 or 2 R8groups);R4is independently selected from for example hydrogen, halo, nitro, cyano, hydroxy, C1-4alkyl, and C1-4alkanoyl;R8is selected from for example hydroxy, —COCOOR9, —C(O)N(R9)(R10), —NHC(O)R9, (R9)(R10)N— and —COOR9;R9and R10are selected from for example hydrogen, hydroxy, C1-4alkyl (optionally substituted by 1 or 2 R13);R13is selected from hydroxy, halo, trihalomethyl and C1-4alkoxy;or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.
REFERENCES:
patent: 3706810 (1972-12-01), Brabander et al.
patent: 4599198 (1986-07-01), Hoover
patent: 4668769 (1987-05-01), Hoover
patent: 4692522 (1987-09-01), Parsons et al.
patent: 4720503 (1988-01-01), Witzel
patent: 4751231 (1988-06-01), Halczenko
patent: 4786641 (1988-11-01), Goldmann
patent: 4794120 (1988-12-01), Manoury
patent: 5863903 (1999-01-01), Lundgren
patent: 5998463 (1999-12-01), Hulin
patent: 2004/0002495 (2004-01-01), Sher et al.
patent: 2004/0142938 (2004-07-01), Sher et al.
patent: 2004/0220229 (2004-11-01), Bussolotti et al.
patent: 2004/0266768 (2004-12-01), Schoenafinger et al.
patent: 200740 (1983-06-01), None
patent: 4445968 (1996-06-01), None
patent: 697403 (1996-02-01), None
patent: 0846464 (1998-06-01), None
patent: 0884050 (1998-12-01), None
patent: 0978279 (2000-02-01), None
patent: 1149580 (2001-02-01), None
patent: 1177791 (2001-07-01), None
patent: 1125580 (2001-08-01), None
patent: 1134213 (2001-09-01), None
patent: 1136071 (2001-09-01), None
patent: 1 338 594 (2003-08-01), None
patent: 1 340 500 (2003-09-01), None
patent: 1088824 (2004-01-01), None
patent: 1145717 (2004-05-01), None
patent: 2081747 (1996-03-01), None
patent: 021247565 (1990-05-01), None
patent: 04179949 (1992-06-01), None
patent: 2001 089368 (2001-04-01), None
patent: 2001 206856 (2001-07-01), None
patent: 2001247565 (2001-09-01), None
patent: 2004196702 (2004-07-01), None
patent: WO-93/25574 (1993-12-01), None
patent: WO-95/24391 (1995-09-01), None
patent: WO-96/39384 (1996-12-01), None
patent: WO-96/39385 (1996-12-01), None
patent: WO-97/09040 (1997-03-01), None
patent: WO-97/31901 (1997-09-01), None
patent: WO-97/45425 (1997-12-01), None
patent: WO-98/27108 (1998-06-01), None
patent: WO-98/40353 (1998-09-01), None
patent: WO-98/50359 (1998-11-01), None
patent: WO-99/26659 (1999-06-01), None
patent: WO-99/36393 (1999-07-01), None
patent: WO-00/42213 (2000-07-01), None
patent: WO-00/47206 (2000-08-01), None
patent: WO-01/05954 (2001-01-01), None
patent: WO-01/23347 (2001-04-01), None
patent: 01/32622 (2001-05-01), None
patent: WO-01/32654 (2001-05-01), None
patent: WO-01/52825 (2001-07-01), None
patent: WO-01/68055 (2001-09-01), None
patent: WO-01/68092 (2001-09-01), None
patent: WO-01/68603 (2001-09-01), None
patent: WO-01/94300 (2001-12-01), None
patent: WO-01/96311 (2001-12-01), None
patent: WO-01/96347 (2001-12-01), None
patent: 02/20530 (2002-03-01), None
patent: WO-02/26714 (2002-04-01), None
patent: WO-02/34718 (2002-05-01), None
patent: WO-02/080844 (2002-10-01), None
patent: WO-02/096864 (2002-12-01), None
patent: WO-02/098348 (2002-12-01), None
patent: WO-03/037864 (2003-05-01), None
patent: 03/045920 (2003-06-01), None
patent: 03/072570 (2003-09-01), None
patent: 03/074484 (2003-09-01), None
patent: 03/074485 (2003-09-01), None
patent: 03/074517 (2003-09-01), None
patent: 03/074531 (2003-09-01), None
patent: 03/074532 (2003-09-01), None
patent: 03/091213 (2003-11-01), None
patent: 2004/031193 (2004-04-01), None
patent: 2004/031194 (2004-04-01), None
patent: 2004/041780 (2004-05-01), None
patent: 2004/092158 (2004-10-01), None
patent: 2004113345 (2004-12-01), None
patent: 2005/013975 (2005-02-01), None
patent: 2005/013981 (2005-02-01), None
patent: 2005/018637 (2005-03-01), None
patent: 2005/019172 (2005-03-01), None
patent: 2005/020985 (2005-03-01), None
patent: 2005/020986 (2005-03-01), None
patent: 2005/020987 (2005-03-01), None
Parsons, J Med Chem, vol. 32, pp. 1681-1685, 1989.
Crochet, R.A., et al., J. Het. Chem., “Synthesis of Substituted Thieno[2,3-b] pyrroles,” vol. 11, 143-150 (Apr. 1974).
Teague, J., “Mobilisation of Tissue Glycogen Following Inhibition of Glycogen Phosphorylase in fa/fa Rat,” Diabetes, 52, Supp. 2, A365, 1521-P.
Vertigan, H., “Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents,” Diabetologia, 47, Supp. 1, 589, A214.
Font, M. et al. “Indoles and pyridazino[4,5-b]indoles as nonnucleoside analog inhibitors of HIV-1 reverse transcripptase”, European Journal Med Chem (1995), 30(12), 963-71.
Lin, T. et al. “Effects of Protein Binding and Experimental Disease States on Brain Uptake of Benzodiazepines in Rats”, J Pharmacology & Eptl Therapeutics (1990), 253(1), 45-50.
Varnavas, A. et al. “Quinolone Derivatives: Synthesis and Binding Evaluation on Cholecystokinin Receptors”, Farmaco (1996), 51(5), 341-350.
Parsons, W H. et al. “Cholecystokinin Antagonists. Synthesis and Biological Evaluation of 3-Substitued Benzolactams”, J Med Chem (1989), 32(8), 1681-5.
Vertigan, H. et al. “Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents”, EASD Munich 2004.
Bartlett, J. et al. “In Vitro and In Vivo Profile of Gpi688, a Novel, Potent Inhibitor of Glycogen Phosphorylase”, ADA San Diego 2005.
Green, A R. et al. “The Glycogenic Action of Protein Targeting to Glycogen in Hepatocytes Involves Multiple Mechanisms Including Phosphorylase Inactivation and Glycogen Synthase Translocation”, J Biol Chem, 279(45), 46474-46482, 2004.
Roberts, P A. et al. “The temporal relationship between glycogen phosphorylase and activation of the pyruvate dehydrogenase complex during adrenaline infusion in resting canine skeletal muscle”, J Physiology-London 545(1), 297-304, 2002.
Simpson, I. et al. “Novel Orally Active Amino-indan Inhibitors of Glycogen Phosphorylase”, Cambridge Med Chem Conference, Sep. 2005. Poster EOM.
Birch, A., et al., “Novel Thienopyrrole Glycogen Phosphorylase Inhibitors: In Vitro SAR and Crystallographic Studies,” Poster, AstraZeneca UK, CVGI Research, Mereside, Alderley Park, Macclesfield, Cheshire.
Crochet, R.A., et al., “Synthesis of Substituted Thieno[2,3-b] pyrroles,” vol. 11, 143-150 (Apr. 1974).
Freeman, S., et al., “Effect of Glucose on Rat and Human Liver Glycogen Phosphorylasea Activity and Potency of a Glycogen Phosphoylase Inhibitor,” Diabetes, 52, Supp., 1470-P, A340.
Hartman, G.D., et al., “The Synthesis of 5-Alkylaminomethylthieno[2,3-b]Pyrrole-5-Sulfonamides,” Heterocycles, 29(10):1943-1949 (1989).
Hoover, D.J., et al., “Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase,” J. Med. Chem., 41:2934-2938 (1998).
Hudson, S., et al., “The effect of a glycogen phosphorylase inhibitor upon muscle fatigue in anaesthetised rats,” J. Physiol., 539:52-53 (2002).
Jakobsen, P., et al., “Iminosugars: Potential Inhibitors of Liver Glycogen Phosphorylase.,” Bioorganic Med. Chem., 9:733-744 (2001).
Martin, W.H., et al., “Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo,” PNAS, 95:1776-1781 (Feb. 1998).
McCormack, J.G., et al., “Pharmacological Approaches to Inhibit Endogenous Glucose P
Birch Alan Martin
Morley Andrew David
AstraZeneca AB
Seaman D. Margaret
LandOfFree
Indole-amide derivatives and their use as glycogen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole-amide derivatives and their use as glycogen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole-amide derivatives and their use as glycogen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3794068